News

Date
Title
Sort By:
09/28/23
SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance
08/28/23
SCYNEXIS to Participate in September Investor Conferences
08/14/23
SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update
07/20/23
SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China
06/21/23
SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK
06/15/23
SCYNEXIS to Participate in the Maxim Group Virtual Healthcare Conference
05/12/23
SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)
05/11/23
SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update
04/13/23
SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark
03/31/23
SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update